A Complete Guide to

Pharma and Biotech Patent Due Diligence

In a Changing Legal and Regulatory Landscape

Thursday, December 04, 2003

About

DO YOU HAVE THE TOOLS AND STRATEGIES YOU NEED TO CONDUCT THOROUGH - AND ACCURATE - PATENT DUE DILIGENCE?

Pharmaceutical and biotech patents are the key drivers for most life sciences transactions. Where a patent is in its life cycle, its validity, its scope and enforceability are critical questions that must be asked and answered before the close of any deal. Given the complexities and the high stakes involved in these transactions, it is critical that those conducting due diligence know not only what they're looking for and how to find it, but how the changing laws and regulations affecting pharmaceutical and biotech patents influence the outcome of their inquiries.

This information-packed American Conference Institute publication was developed to give you the state-of-the-art tools required to conduct a thorough and accurate due diligence review of the patent portfolios that are crucial to your deal. You will read from expert faculty that will take you step-by-step through the approaches and disciplines that result in due diligence. Also mentioned in this publication is the dynamic state of the law surrounding pharmaceutical and biotech intellectual property and how to interpret and apply it in the context of today's transactions.

Contents & Contributors

About

DO YOU HAVE THE TOOLS AND STRATEGIES YOU NEED TO CONDUCT THOROUGH - AND ACCURATE - PATENT DUE DILIGENCE?

Pharmaceutical and biotech patents are the key drivers for most life sciences transactions. Where a patent is in its life cycle, its validity, its scope and enforceability are critical questions that must be asked and answered before the close of any deal. Given the complexities and the high stakes involved in these transactions, it is critical that those conducting due diligence know not only what they're looking for and how to find it, but how the changing laws and regulations affecting pharmaceutical and biotech patents influence the outcome of their inquiries.

This information-packed American Conference Institute publication was developed to give you the state-of-the-art tools required to conduct a thorough and accurate due diligence review of the patent portfolios that are crucial to your deal. You will read from expert faculty that will take you step-by-step through the approaches and disciplines that result in due diligence. Also mentioned in this publication is the dynamic state of the law surrounding pharmaceutical and biotech intellectual property and how to interpret and apply it in the context of today's transactions.

Contents & Contributors

BIOTECH AND PHARMA TECHNOLOGY DUE DILIGENCE: OFFENSIVE AND DEFENSIVE STRATEGIES
Thomas W. MacAllister, J.D., Ph.D., Sucampo Pharmaceuticals, Inc.

WHEN ENOUGH IS ENOUGH: PRACTICAL IP DUE DILIGENCE IN PHARMACEUTICAL TRANSACTIONS
0 Robert T. Hrubiec, Ph.D., J.D., Cephalon, Inc.

DUE DILIGENCE RISKS IN IP TRANSACTIONS
John W. Ryan, Dechert

RISK ASSESSMENT IN PATENT DUE DILIGENCE
Seth Jacobs, Pfizer, Inc.

ASSESSING A COMPANY'S FREEDOM TO OPERATE
Anthony Sabatelli, Ph.D., J.D., Rib-X Pharmaceuticals, Inc.

ADDRESSING POTENTIAL BLOCKING PATENTS
Elizabeth Stotland Weiswasser, Weil Gotshal & Manges, LLP

IP DUE DILIGENCE AND VALUATION: INDUSTRY/UNIVERSITY COLLABORATIONS
Abram Goldgfinger, New York University

PATENT DUE DILIGENCE FOR INDUSTRY/UNIVERSITY COLLABORATIONS
Stacy L. Taylor, Foley & Lardner

RECENT CASE LAW AFFECTING PATENT DUE DILIGENCE
Richard Peet, Ph.D., J.D., Foley & Lardner

HATCH WAXMAN REFORM AND PATENT DUE DILIGENCE
M. Veronica Mullally, Orrick Herrington & Sutcliffe



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0